These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30808874)

  • 1. The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells.
    Abeykoon JP; Paludo J; Nowakowski KE; Stenson MJ; King RL; Wellik LE; Wu X; Witzig TE
    Blood Cancer J; 2019 Feb; 9(3):24. PubMed ID: 30808874
    [No Abstract]   [Full Text] [Related]  

  • 2. CRM1 as a new therapeutic target for non-Hodgkin lymphoma.
    Han X; Wang J; Shen Y; Zhang N; Wang S; Yao J; Shi Y
    Leuk Res; 2015 Jan; 39(1):38-46. PubMed ID: 25466285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
    Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
    Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase (AID).
    Shivarov V; Dimitrova P; Vassilev T
    Haematologica; 2013 Sep; 98(9):e111-3. PubMed ID: 24006409
    [No Abstract]   [Full Text] [Related]  

  • 6. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.
    Salas Fragomeni RA; Chung HW; Landesman Y; Senapedis W; Saint-Martin JR; Tsao H; Flaherty KT; Shacham S; Kauffman M; Cusack JC
    Mol Cancer Ther; 2013 Jul; 12(7):1171-9. PubMed ID: 23615632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Providing activation-induced cytidine deaminase (AID) to nuclear export inhibitors. Response to: "Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase".
    Azmi AS; Mohammad RM
    Haematologica; 2013 Sep; 98(9):e123. PubMed ID: 24006415
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
    Kojima K; Kornblau SM; Ruvolo V; Dilip A; Duvvuri S; Davis RE; Zhang M; Wang Z; Coombes KR; Zhang N; Qiu YH; Burks JK; Kantarjian H; Shacham S; Kauffman M; Andreeff M
    Blood; 2013 May; 121(20):4166-74. PubMed ID: 23564911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.
    Liu S; Qiao W; Sun Q; Luo Y
    J Med Chem; 2021 Nov; 64(21):15534-15548. PubMed ID: 34669417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.
    Azmi AS; Al-Katib A; Aboukameel A; McCauley D; Kauffman M; Shacham S; Mohammad RM
    Haematologica; 2013 Jul; 98(7):1098-106. PubMed ID: 23403316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Cancer at the Nuclear Pore.
    Azmi AS; Mohammad RM
    J Clin Oncol; 2016 Dec; 34(34):4180-4182. PubMed ID: 27863200
    [No Abstract]   [Full Text] [Related]  

  • 12. XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis.
    Boons E; Nogueira TC; Dierckx T; Menezes SM; Jacquemyn M; Tamir S; Landesman Y; Farré L; Bittencourt A; Kataoka K; Ogawa S; Snoeck R; Andrei G; Van Weyenbergh J; Daelemans D
    Blood Cancer J; 2021 Feb; 11(2):27. PubMed ID: 33563902
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.
    Garg M; Kanojia D; Mayakonda A; Said JW; Doan NB; Chien W; Ganesan TS; Chuang LS; Venkatachalam N; Baloglu E; Shacham S; Kauffman M; Koeffler HP
    Oncotarget; 2017 Jan; 8(5):7521-7532. PubMed ID: 27893412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the nuclear transport machinery by rational drug design.
    Mao L; Yang Y
    Curr Pharm Des; 2013; 19(12):2318-25. PubMed ID: 23082981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms.
    Meissner T; Krause E; Vinkemeier U
    FEBS Lett; 2004 Oct; 576(1-2):27-30. PubMed ID: 15474004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A low toxic CRM1 degrader: Synthesis and anti-proliferation on MGC803 and HGC27.
    Xu HW; Jia S; Liu M; Li X; Meng X; Wu X; Yu L; Wang M; Jin CY
    Eur J Med Chem; 2020 Nov; 206():112708. PubMed ID: 32810752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection.
    Lu C; Figueroa JA; Liu Z; Konala V; Aulakh A; Verma R; Cobos E; Chiriva-Internati M; Gao W
    Curr Cancer Drug Targets; 2015; 15(7):575-92. PubMed ID: 26324128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeic acid phenethyl ester (CAPE) revisited: Covalent modulation of XPO1/CRM1 activities and implication for its mechanism of action.
    Wu S; Zhang K; Qin H; Niu M; Zhao W; Ye M; Zou H; Yang Y
    Chem Biol Drug Des; 2017 May; 89(5):655-662. PubMed ID: 27863053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
    Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
    PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crm1 is a mitotic effector of Ran-GTP in somatic cells.
    Arnaoutov A; Azuma Y; Ribbeck K; Joseph J; Boyarchuk Y; Karpova T; McNally J; Dasso M
    Nat Cell Biol; 2005 Jun; 7(6):626-32. PubMed ID: 15908946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.